Capricor Therapeutics (NASDAQ:CAPR) Given Buy Rating at HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $40.00 target price on the biotechnology company’s stock.

Capricor Therapeutics Trading Up 0.8 %

Capricor Therapeutics stock opened at $5.12 on Tuesday. The stock has a 50 day moving average of $4.35 and a two-hundred day moving average of $5.18. Capricor Therapeutics has a twelve month low of $2.68 and a twelve month high of $7.28. The stock has a market capitalization of $163.73 million, a price-to-earnings ratio of -5.89 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Equities analysts predict that Capricor Therapeutics will post -1.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CAPR. BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics in the first quarter valued at about $40,000. Main Street Financial Solutions LLC boosted its stake in shares of Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 7,500 shares in the last quarter. Rhumbline Advisers acquired a new position in Capricor Therapeutics during the second quarter worth $147,000. Jump Financial LLC purchased a new position in Capricor Therapeutics in the fourth quarter worth $258,000. Finally, Bank of New York Mellon Corp lifted its holdings in Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 9,040 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.